Weekly Recap | AKESO +7.92%, ivonescimab Phase III hits endpointWeekly Review·1 day ago, 12:06 AM09926-5.78%
Weekly Recap | BEONE MEDICINES +1.36%, FDA nod and 385% interim profit jumpWeekly Review·1 day ago, 11:52 PM06160-0.71%
Weekly Recap | INNOVENT BIO +8.04%, earnings beat estimatesWeekly Review·1 day ago, 11:21 PM01801-0.09%
Weekly Recap | CSPC PHARMA +1.44%, six pipeline milestones in one weekWeekly Review·1 day ago, 11:12 PM01093-1.55%
Weekly Recap | SBP GROUP +0.27%, consensus target above spotWeekly Review·1 day ago, 11:10 PM01177-0.71%
Sino Biopharm wins NMPA nod to start LM-364 Nectin-4 TME ADC trial in solid tumorsPUBT·2 days ago, 03:35 AM01177-0.71%
CICC Says WUXI BIO Profitability Improves, Raises TP 25% to HKD60 and Lifts Earnings ForecastsAASTOCKS News·2 days ago, 03:00 AMWXXWY+0.70%02269+0.30%
CMSI Raises INNOVENT BIO TP to HKD122, Long-term Earnings Growth Outlook Supports ValuationAASTOCKS News·2 days ago, 01:36 AM01801-0.09%
Akeso says Phase III ivonescimab-chemo trial in biliary tract cancer meets overall survival endpointPUBT·2 days ago, 09:45 PM09926-5.78%
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer'sPR Newswire·2 days ago, 09:44 PM09926-5.78%
AKESO Opens 6.1% Lower; 1H26 Loss Narrows to RMB424 MillionAASTOCKS News·2 days ago, 08:36 PM09926-5.78%
